Values First Advisors Inc. Cuts Stock Position in Agenus Inc. (NASDAQ:AGEN)

Values First Advisors Inc. cut its holdings in Agenus Inc. (NASDAQ:AGEN) by 19.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,894 shares of the biotechnology company’s stock after selling 3,186 shares during the quarter. Values First Advisors Inc. owned 0.05% of Agenus worth $35,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Apollon Wealth Management LLC purchased a new position in shares of Agenus in the fourth quarter valued at $55,000. EP Wealth Advisors LLC purchased a new position in Agenus during the third quarter worth $55,000. Point72 DIFC Ltd boosted its stake in Agenus by 380.0% during the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after buying an additional 11,542 shares during the period. HighTower Advisors LLC boosted its stake in Agenus by 46.1% during the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after buying an additional 7,530 shares during the period. Finally, Exchange Traded Concepts LLC boosted its stake in Agenus by 52.0% during the third quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock worth $151,000 after buying an additional 9,422 shares during the period. 61.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Agenus has an average rating of “Hold” and an average target price of $10.00.

Agenus Trading Up 1.2 %

NASDAQ:AGEN opened at $3.50 on Friday. Agenus Inc. has a twelve month low of $2.50 and a twelve month high of $19.69. The company has a market cap of $82.11 million, a price-to-earnings ratio of -0.31 and a beta of 1.31. The stock has a fifty day simple moving average of $3.26 and a 200-day simple moving average of $4.18.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.